A Rare Case Report of Sitagliptin-Induced Angioedema

Cureus. 2022 Oct 8;14(10):e30077. doi: 10.7759/cureus.30077. eCollection 2022 Oct.

Abstract

Sitagliptin, a dipeptidyl peptidase-4 inhibitor, is used for the treatment of type 2 diabetes mellitus. Sitagliptin-induced angioedema has increased with the simultaneous use of angiotensin receptor blockers and angiotensin-converting enzyme inhibitors. We present a rare case of a 50-year-old female diagnosed with sitagliptin-induced angioedema. On examination, she had both upper and lower lip swelling without any respiratory compromise. On further investigation, her C1 esterase inhibitor level was normal. After stopping sitagliptin, her symptoms resolved. Thus, cautious use of dipeptidyl peptidase-4 inhibitor is advised.

Keywords: angioedema; c1 esterase inhibitor; diabetes mellitus; hereditary angioedema; sitagliptin.

Publication types

  • Case Reports